ProMIS Neu­ro­sciences se­cures $20M+ PIPE; Beam Ther­a­peu­tics re­veals da­ta ahead of IND

ProMIS Neu­ro­sciences, a biotech fo­cused on de­vel­op­ing treat­ments for neu­rode­gen­er­a­tive dis­eases, closed a pri­vate in­vest­ment in pub­lic eq­ui­ty, or PIPE, that brought in $20.4 mil­lion.

The fund­ing is set to go to­ward de­vel­op­ing ProMIS’ lead can­di­date, PMN310, a pre­clin­i­cal an­ti-amy­loid ther­a­py de­signed to treat Alzheimer’s dis­ease, ac­cord­ing to a news re­lease on Fri­day. — Tyler Patchen

Beam shares pre­clin­i­cal da­ta on AATD base edit­ing treat­ment ahead of IND

Beam Ther­a­peu­tics said Thurs­day that its base edit­ing treat­ment for al­pha-1 an­tit­rypsin de­fi­cien­cy, or AATD, helped in­crease lev­els of a func­tion­al pro­tein in rats and mice and de­crease lev­els of a mu­tat­ed pro­tein.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER